Diabetic Nephropathy Market is expected to witness a major change in the 7MM during 2019-2032 | Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Kyowa Kirin, Teijin America

September 05 22:32 2023
Diabetic Nephropathy Market is expected to witness a major change in the 7MM during 2019-2032 | Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Kyowa Kirin, Teijin America
Diabetic Nephropathy Market

“The Diabetic Nephropathy Market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Diabetic Nephropathy pipeline products will significantly revolutionize the Pertussis market dynamics”

 

The Diabetic Nephropathy market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Diabetic Nephropathy market size from 2019 to 2032. The report also covers current Diabetic Nephropathy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Diabetic Nephropathy Market Report

  • The Diabetic Nephropathy Market is expected to grow by factors like an increase in the patient pool, expected entry of emerging therapies.
  • The leading Diabetic Nephropathy Companies working in the market include Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Kyowa Kirin, Teijin America, Boehringer Ingelheim/Eli Lilly and Company, Chinook Therapeutics/Abbvie, Mitsubishi Tanabe Pharma, AstraZeneca, Boehringer Ingelheim, CSL Behring, Gilead Sciences, Goldfinch Bio, Novartis Pharmaceuticals, Prokidney, and others.
  • Promising Diabetic Nephropathy Pipeline Therapies in the various stages of development include Propagermanium, Baricitinib, MT-3995, Canagliflozin, Nidufexor, LY3016859, PH3, IW-1973,  Pyridorin (pyridoxamine dihydrochloride), Bindarit, Probucol and Cilostazol, BAY94-8862, RTA 402 (Bardoxolone Methyl), Ketosteril®, BI 690517, Eplerenone, and others.
  • On January 2023, Boehringer Ingelheim announced a study of phase 2 clinical trials for BI 685509. This study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study.
  • On July 2023, Inversago Pharma Inc announced a study of phase 2 clinical trials for INV-202. The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

 

Discover more about therapies set to grab major Diabetic Nephropathy Market Share @ Diabetic Nephropathy Market Size

 

Diabetic Nephropathy Overview

Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It is also known as Diabetic Kidney Disease (DKD). It happens when a person’s kidneys are damaged by elevated blood glucose levels. It is a leading cause of chronic kidney disease and end-stage renal disease (ESRD). The kidneys in ESRD are no longer able to satisfy the demands of everyday life. Kidney failure can occur as a result of ESRD, which can be life-threatening.

 

Diabetic Nephropathy Epidemiology Segmentation in the 7MM

  • Diabetic Nephropathy Stage-Specific Prevalence
  • Diabetic Nephropathy Age-Specific Prevalence
  • Total Diabetic Nephropathy Prevalence (Type 1 and Type 2)
  • Diabetic Nephropathy Prevalence
  • Diabetic Nephropathy Gender-Specific Prevalence

 

Download the report to understand which factors are driving Diabetic Nephropathy Epidemiology Trends @ Diabetic Nephropathy Epidemiological Insights

 

Diabetic Nephropathy Market Insights

In a nutshell, it can be summarized that as a result of discovery of new aspects of disease etiology more potential therapeutic targets are being identified leading to surge in potential therapies are being investigated for the management of Diabetic Nephropathy, it is safe to predict that the treatment space will experience significant reconstitution during the forecast period of 2023–2032.

 

Diabetic Nephropathy Emerging Therapy Assessment

The available therapeutics treatment options in Diabetic Nephropathy Landscape aim to reduce the disease burden. The current market anticipates the emergence of emerging products namely Esaxerenone (Daiichi Sankyo),TMX-049 (Teijin America), CSL346 (CSL Behring) and GFB-887 (Goldfinch Bio).

 

To know more about Diabetic Nephropathy Treatment options, visit @ Diabetic Nephropathy Drugs

 

Diabetic Nephropathy Market Drivers

  • Increased prevalence of diabetes and Diabetic Kidney Disease
  • Annual screening programs
  • Multidisciplinary Care

 

Diabetic Nephropathy Market Barriers

  • Heterogeneous nature of the disease
  • Lack of awareness among the patients and primary care physician
  • Poor access to health insurance and healthcare
  • Treatment challenges

 

Learn more about the Diabetic Nephropathy Pipeline Therapies in clinical trials @ Diabetic Nephropathy Market Landscape

 

Scope of the Diabetic Nephropathy Market Report

  • Coverage- 7MM
  • Diabetic Nephropathy Companies- Bayer, Janssen Pharmaceutical, AstraZeneca (NYSE: AZN), Daiichi Sankyo (NYSE: DSNKY), Kyowa Kirin (NYSE:KYKOF), Teijin America, Boehringer Ingelheim, Eli Lilly and Company (NYSE: LLY), Chinook Therapeutics, Abbvie (NYSE: ABBV), Mitsubishi Tanabe Pharma (NYSE: MTZPY), Boehringer Ingelheim, CSL Behring, Gilead Sciences (NYSE: GILD), Goldfinch Bio, Novartis Pharmaceuticals (NYSE: NVS), Prokidney, and others.
  • Diabetic Nephropathy Pipeline Therapies- Propagermanium, Baricitinib, MT-3995, Canagliflozin, Nidufexor, LY3016859, PH3, IW-1973,  Pyridorin (pyridoxamine dihydrochloride), Bindarit, Probucol and Cilostazol, BAY94-8862, RTA 402 (Bardoxolone Methyl), Ketosteril®, BI 690517, Eplerenone, and others
  • Diabetic Nephropathy Market Dynamics: Market Drivers and Barriers
  • Diabetic Nephropathy Market Access and Reimbursement, Unmet Needs, Analyst Views

 

Discover more about Diabetic Nephropathy Drugs in development @ Diabetic Nephropathy Ongoing Clinical Trials Analysis

 

Table of Content

  1. Key Insights
  2. Diabetic Nephropathy Executive Summary
  3. Competitive Intelligence Analysis for Diabetic Nephropathy
  4. Diabetic Nephropathy: Market Overview at a Glance
  5. Diabetic Nephropathy: Disease Background and Overview
  6. Patient Journey
  7. Diabetic Nephropathy Epidemiology and Patient Population
  8. Diabetic Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
  9. Diabetic Nephropathy Unmet Needs
  10. Key Endpoints of Diabetic Nephropathy Treatment
  11. Diabetic Nephropathy Marketed Products
  12. Diabetic Nephropathy Emerging Therapies
  13. Diabetic Nephropathy: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Diabetic Nephropathy
  17. KOL Views
  18. Diabetic Nephropathy Market Drivers
  19. Diabetic Nephropathy Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/rare-diseases